Company

Biotest - Innovation in haematology,
clinical immunology and intensive care medicine

Further information

Research and development

Specialist for Immune Sciences

Further information

Investor Relations

Create value for our shareholders

Further information

Patients

Biotest products save lives and offer new perspectives to chronically ill patients

Further information

Careers

Passionate to help us save lives?

Further information

Our product range

Haematology Clinical immunology Intensive care medicine

Haematology

For the treatment of Haemophilia A and B, Biotest AG manufactures two preparations which derive from human plasma and are designed for intravenous injection.

Further information

Clinical immunology

Biotest produces several antibody concentrates from human blood plasma which are available as ready-to-use solutions. Biotest offers the IVIG preparation Intratect and different hyperimmunoglobulins with increased antibody titers against cytomegaloviruses (CMV), hepatitis B viruses (HBV) or varicella zoster viruses (VZV).

Further information

Intensive care medicine

Biotest produces several human blood plasma derived concentrates for intensive care medicines. These include Pentaglobin, an IgM enriched immunoglobulin, and other intravenously administered solutions, for the treatment of severe bacterial infections, coagulation disorders, and volume- or protein-substitution.

Further information

Our development pipeline

	Phase 1	Phase 2	Phase 3	Approval	Launch
	IgG Next Generation (BT-595) - Primary Immune Deficiency (PID)
	IgG Next Generation (BT-595) - Idiopathic Thrombocytopenic Purpura (ITP)
	Fibrinogen (BT-524) - Congenital fibrinogen deficiency
	Fibrinogen (BT-524) - Acquired Fibrinogen Deficiency
	Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis
	Trimodulin (BT-086) - Severe community acquired pneumonia
	(BT-063) - Systemic lupus erythematosus
	Indatuximab Ravtansine (BT-062) - Multiple myeloma
	Indatuximab Ravtansine* (BT-062) - Solid tumors
	Tregalizumab (BT-061) - other diseases

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

* Further information under News from research

Press releases

Cytotect(R) CP prevents transmission of Cytomegalovirus...

15.08.2018,

Cytotect(R) CP prevents transmission of Cytomegalovirus (CMV) to the unborn baby in pregnant women who are infected with CMV for the first time- Transmission of CMV from pregnant women to the foetus i ... [More]

Biotest increases revenues to EUR 200.7 million in the ...

14.08.2018,

Biotest increases revenues to EUR 200.7 million in the first half of 2018- EBIT of EUR 0.6 million despite expenses of EUR 23.7 million for the Biotest Next Level project- Successful qualification of ... [More]

Biotest has closed a transaction to sell all of its pla...

01.08.2018,

Biotest has closed a transaction to sell all of its plasma collection centres in the United States to Grifols- Federal Trade Commission (FTC) approved sale of Biotest US Corporation and its operating ... [More]

Phase IIa study demonstrates favorable safety and toler...

19.07.2018,

Phase IIa study demonstrates favorable safety and tolerability profile for Biotest's monoclonal antibody BT-063 for treatment of systemic lupus erythematosus (SLE)- Study meets primary endpoint for sa ... [More]

Biotest AG opens third plasma collection centre in Czec...

20.06.2018,

Biotest AG opens third plasma collection centre in Czech Republic- 19 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 20 June 2018. Biotest received an operating permit ... [More]

Release according to Article 40, Section 1 of the WpHG ...

20.06.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights Acquisit ... [More]

Large data analysis for DSA after lung transplantation ...

29.05.2018,

Large data analysis for DSA after lung transplantation confirms impressive therapy outcome with Pentaglobin(R)- The development of donor specific antibodies (DSA) can lead to graft rejection and thus ... [More]

Efficacy and safety of Cytotect(R) CP was demonstrated ...

23.05.2018,

Efficacy and safety of Cytotect(R) CP was demonstrated in patients after stem cell transplantation- 78% of "difficult-to-treat" patients responded to Cytotect(R) CP administration- 70% of patients cle ... [More]

Biotest increases revenues in the first quarter 2018 by...

15.05.2018,

Biotest increases revenues in the first quarter 2018 by 34%- Guidance confirmed- Q1 EBIT totalled to EUR -3.0 million after EUR-33.2 million in Q1 2017Dreieich, 15 May 2018. In the first quarter of 20 ... [More]

Biotest AG: Annual general meeting approves payout of d...

15.05.2018,

Biotest AG: Annual general meeting approves payout of dividend- Dividend payout of EUR 0.04 per preference shareDreieich/ Frankfurt a. M., 15 May 2018. At the annual general meeting (AGM) held on 15 M ... [More]

New data from Biotest's monoclonal antibody-drug-conjug...

03.05.2018,

New data from Biotest's monoclonal antibody-drug-conjugate (ADC) BT-062 in the therapy of solid tumors- Good tolerability and signs of efficacy in phase I/IIa clinical study- Very good effectiveness w ... [More]

Biotest reaches 2017 profit guidance

22.03.2018,

Biotest reaches 2017 profit guidance- Adjusted EBIT stable- Five new plasmapheresis centres opened in Europe- Biotest Next Level: building acceptance obtained and successful "Good Manufacturing Practi ... [More]

First patient with acquired fibrinogen deficiency treat...

15.03.2018,

First patient with acquired fibrinogen deficiency treated in clinical phase III study of Biotest AG - Important milestone reached in the clinical development programme of fibrinogen concentrate- Phase ... [More]

Biotest supports a large international registry study t...

13.03.2018,

Biotest supports a large international registry study to record data on use of Pentaglobin(R) in patients with severe bacterial infections- High medical need due to high mortality and large pati ... [More]

Biotest reaches FY 2017 EBIT guidance

27.02.2018,

Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest reaches FY 2017 EBIT guidanceDreieich, 27 February 2018. According to preliminary and unaudited figures, the Biotest ... [More]

Tiancheng intends to enter into a domination and profit...

08.02.2018,

Announcement according to Article 17 European Market Abuse Regulation (MAR)Tiancheng intends to enter into a domination and profit and loss transfer agreement with Biotest AGDreieich, 8 February 2018. ... [More]

Release according to Article 40, Section 1 of the WpHG ...

02.02.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights Acquisit ... [More]

Release according to Article 40, Section 1 of the WpHG ...

01.02.2018,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights Acquisit ... [More]

Creat takeover of Biotest closed

31.01.2018,

Creat takeover of Biotest closed- Transfer of tendered shares completed- Majority shareholding (approx. 90% of Biotest AG's ordinary shares and voting share capital) of Creat in Biotest Dre ... [More]

Biotest AG opens second plasma collection centre in Cze...

24.01.2018,

Biotest AG opens second plasma collection centre in Czech Republic- 19 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 24 January 2018. Biotest received an operating per ... [More]

Careers

Careers

Passionate to help us save lives?

Further information

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.

Further information